Proliferative stimulation of the vascular endothelin-1 axis in vitro and ex vivo by infection with Chlamydia pneumoniae

Thrombosis and Haemostasis

Volumn 102, Issue 4, 2009, Pages 743-753

  Kern, Jan Marco ^a   Maass, Viola ^a   Rupp, Jan ^b   Maass, Matthias ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Endothelial cells; Endothelin 1; Proliferation

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL; ARTICLE; C57BL MOUSE; CELL PROLIFERATION; CELL STRAIN HEPG2; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CORONARY BLOOD VESSEL; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL PROLIFERATION; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY VESSELS; ENDOTHELIN-1; HEP G2 CELLS; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SIGNAL TRANSDUCTION;

EID: 72949118706     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-02-0128     Document Type: Article

References (47)

1. Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis. Circulation 2002; 105: 1135-1143.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
3. Prasad A, Zhu J, Halcox HPJ, Quyyumi AA, et al. Predisposition to atherosclerosis by infections-Role of endothelial dysfunction. Circulation 2002; 106: 184-190.
4. Maass M, Jahn J, Gieffers J, et al. Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J Infect Dis 2000; 181: 449-451.
5. Campbell LA, O'Brien ER, Cappucio AL, et al. Detection of Chlamydia pneumoniae (TWAR) in human coronary atherectomy tissues. J Infect Dis 1995; 172: 585-588.
6. Kuo CC, Shor A, Campbell LA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-849.
7. Maass M, Bartels C, Engel PM, et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 187: 103-106.
8. Rupp J, Hellwig-Bürgel T, Wobbe V, et al. Chlamydia pneumoniae infection promotes a proliferative phenotype in the vasculature through Egr-1 activation in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102: 3447-3452.
9. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomised controlled trial. JAMA 2003; 290: 1459-1466.
10. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-1645.
11. Anderson JL, Muhlestein JB. Antibiotic trials for coronary artery disease. Tex Heart Inst J 2004; 31: 33-38.
12. Jaff MR, Dale RA, Creager MA, et al. Anti-Chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in chlamydia pneumoniae seropositive patients (PROVIDENCE-1). Circulation 2009; 119: 452-458.
13. Gieffers J, Füllgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-356.
14. Gieffers J, Rupp J, Gebert A, et al. First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae. Antimicrob Agents Chemother 2004; 48: 1402-1405.
15. Böhm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007; 76: 8-18.
16. Ivey ME, Osman N, Little PJ. Endothelin-1 signalling in vascular smooth muscle: Pathways controlling cellular associated with atherosclerosis. Atherosclerosis 2008; 199: 237-247.
17. Ishizawa K, Yoshizumi M, Tsuchiya K, et al. Dual effect of Endothelin-1: induction of mesangial cell migration and facilitation of monocyte recruitment through MCP-1 production by mesangial cells. Hypertens Res 2004; 27: 433-440.
18. Lerman A, Edwards BS, Hallett JW. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
19. Ohlstein EH, Arleth A, Bryan H. The selective endothelin ETA receptor antagonist BQ 123 antagonizes endothelin-1 mediated mitogenesis. Eur J Pharmacol 1992; 13: 85-88.
20. Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003; 107: 1053-1058.
21. Ak G, Buyukberber S, Sevince A, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patiens with type 2 diabetes mellitus. J Diabetes Complications 2001; 15: 150-157.
22. Khan IA. Role of endothelin-1 in myocardial infarction. Chest 2005; 127: 1474-1476.
23. Dhaun N, Pollock DM, Goddard J et al. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 2007; 28: 573-579.
24. Maass M, Harig U. Evaluation of culture conditions used for isolation of Chlamydia pneumoniae. Am J Clin Path 1995; 103: 141-148.
25. Winer J, Jung CS, Shackel I, et al. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring of gene expression in cardiac myocytes in vitro. Anal Biochem 1999; 270: 41-49.
26. Yang Z, Oemar BS, Carrel T, et al. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation 1998; 97: 181-187.
27. Rupprecht HJ, Blankenberg S, Bickel C, et al. Impact of viral and bacterial infectious burden on longterm prognosis in patients with coronary artery disease. Circulation 2001; 104: 25-31.
28. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in the coronary artery atheroma plaque. South Afr Med J 1992; 82: 158-161.
29. Gaydos CA, Summersgill JT, Sahney NN, et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996; 64: 1614-1620.
30. Godzik KL, O'Brien ER, Wang AK, et al. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 1995; 33: 2411-2414.
31. Summersgill JT, Molestina RE, Miller RD, Ramirez JA. Interactions of Chlamydia pneumoniae with human endothelial cells. J Infect Dis 2000; 181: 479-482.
32. Fryer RH, Schwobe EP, Woods, et al. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med 1997; 45: 168-174.
33. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression: a potential link to accelerated atherosclerosis. Circulation 1999; 100: 1369-1373.
34. Matsuura A, Yamochi W, Hirata KI, et al. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 1998; 32: 89-95.
35. Hayasaki Y, Nakajiama M, Kitano Y, et al. ICAM-1 expression on cardiac myocytes and aortic endothelial cells via their specific endothelin receptor subtype. Biochem Biophys Res Comm 1996; 229: 817-824.
36. Hohnemeier H, Pinto YM, Horkay F, et al. Endothelin-converting-enzyme-1 mRNA expression in human cardiovascular diseases. J Cardiovasc Pharmacol 1998; 31: 52-54.
37. Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91: 1367-1373.
38. Shah R. Endothelins in health and disease. Eur J Int Med 2007; 18: 272-282.
39. Woods M, Mitchell JA, Wood EG, et al. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol 1999; 55: 902-909.
40. Zeither AM, Ihling C, Pistorius K, et al. Increased tissue edothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994; 344: 1405-1406.
41. Woods M, Wood EG, Bardswell SC, et al. Role for nuclear factor-kappa B and signal transducer and activator of transcription 1/ interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Mol Pharmacol 2003; 64: 923-931.
42. 2+. Life Sci 2008; 82: 764-771.
43. Böhm F, Beltran E, Pernow J. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. J Int Med 2005; 257: 263-271.
44. Halcox JPJ, Nour KRA, Zalos G, et al. Endogenous endothelin in human coronary vascular function. Differential contribution of endothelin receptor types A and B. Hypertension 2007; 49: 1134-1141.
45. Kowala MC, Rose PM, Stein PD. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamster fed cholesterol. Am J Pathol 1995; 146: 819-826.
46. Barton M, Haudenschild CC, d'Uscio LV. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apoEdeficient mice. Proc Natl Acad Sci USA 1998; 95: 14367-14372.
47. Kern JM, Maass V, Maass M. Molecular pathogenesis of chronic Chlamydia pneumoniae infection: a brief overview. Clin Microbiol Infect 2009; 15: 36-41.